Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Income from Continuing Operations of 44551000.0 for Q1 2026, down 195.02% year-over-year from 46885000.0 in Q1 2025, and down 51.08% quarter-over-quarter from 29489000.0 in Q4 2025.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 44551000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 195.02% year-over-year to 44551000.0; the TTM figure through Mar 2026 stood at 113416000.0 (down 583.65% YoY), while the FY2025 annual figure was 21980000.0, up 60.33% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 44551000.0, down from 29489000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 46885000.0 in Q1 2025, with the low at 64823000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 30310000.0 (2024), against an average of 23923235.29.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations plunged 463.48% in 2022, then surged 246.58% in 2025.
- Monte Rosa Therapeutics' Income from Continuing Operations stood at 30782000.0 in 2022, then retreated by 8.02% to 33252000.0 in 2023, then jumped by 192.43% to 30734000.0 in 2024, then plunged by 195.95% to 29489000.0 in 2025, then tumbled by 51.08% to 44551000.0 in 2026.
- Business Quant data shows GLUE's Income from Continuing Operations at 44551000.0 in Q1 2026, 29489000.0 in Q4 2025, and 27081000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.42 Bn | 782.73 Mn | - | -43.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.40 Mn |
| Mar 31, 2026 | -44.55 Mn |
| Dec 31, 2025 | -38.92 Mn |
| Sep 30, 2025 | -27.08 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | 46.89 Mn |
| Dec 31, 2024 | 30.73 Mn |
| Sep 30, 2024 | -23.86 Mn |
| Jun 30, 2024 | -30.31 Mn |
| Mar 31, 2024 | -31.99 Mn |
| Dec 31, 2023 | -33.25 Mn |
| Sep 30, 2023 | -34.88 Mn |
| Jun 30, 2023 | -35.18 Mn |
| Mar 31, 2023 | -32.04 Mn |
| Dec 31, 2022 | -30.78 Mn |
| Sep 30, 2022 | -27.32 Mn |
| Jun 30, 2022 | -26.47 Mn |
| Mar 31, 2022 | -24.15 Mn |
| Dec 31, 2021 | -23.37 Mn |
| Sep 30, 2021 | -19.86 Mn |